Mylan Laboratories Limited Febuxostat Export Data — India (DGFT 2022–2026)

Name: Mylan Laboratories Limited Febuxostat Export Records India — #13 Exporter, 16 Shipments, $414.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Febuxostat

India Pharmaceutical Trade Intelligence

$48.9M182 Suppliers91 CountriesHS 30049099

ExportsIndia → PHILIPPINES52.3%India → UNITED STATES23.7%

ImportsCHINA → India$10.6K UNITED STATES → India$5.5K

#1 Supplier: AJANTA PHARMA #1 Buyer: UNILAB INC

Mylan Laboratories Limited — Febuxostat Exporter #13 | $414.0K Trade Value | TransData Nexus | TransData Nexus

Mylan Laboratories Limited — Febuxostat Exporter Profile

Indian Pharmaceutical Exporter · #13 for Febuxostat · $414.0K export value · DGFT Verified

Mylan Laboratories Limited is the #13 Indian exporter of Febuxostat with $414.0K in export value and 16 verified shipments. Mylan Laboratories Limited holds a 0.8% market share in Febuxostat exports across 5 countries. The company exports 91 pharmaceutical products worth $634.8M across 26 therapeutic categories.

Mylan Laboratories Limited — Febuxostat Export Profile: Buyers & Destinations

Mylan Laboratories Limited Febuxostat export treemap — buyers and destination countries | TransData Nexus

Where Does Mylan Laboratories Limited Export Febuxostat?

Country	Value	Shipments	Share
NETHERLANDS	$116.0K	6	37.1%
FRANCE	$100.0K	2	32.0%
ITALY	$73.3K	4	23.4%
GERMANY	$13.7K	2	4.4%
BELGIUM	$10.0K	2

Who Are the Top Buyers of Febuxostat from Mylan Laboratories Limited?

Buyer	Country	Value	Orders
XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO	NETHERLANDS	$312.9K	16

Mylan Laboratories Limited supplies Febuxostat to 1 buyers globally. The largest buyer is XXLANXXRELXXD LXXITEXX NEXXNHAXXCOUXX MXXAHIXX RO (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Febuxostat Formulations Does Mylan Laboratories Limited Export?

Product Description / Formulation	Value	Shipments
FEBUXOSTAT TAB 120MG 28BL FR MY	$100.0K	2
FEBUXOSTAT TAB 80MG 28BT IT MY	$65.1K	2
FEBUXOSTAT TAB 80MG 84BL CZ MY	$44.8K	1
FEBUXOSTAT TAB 120MG 14BL BG MY	$31.5K	2
FEBUXOSTAT TAB 80MG 28BL CZ MY 2	$20.7K	1
FEBUXOSTAT TAB 80MG 14BL BGMY	$19.0K	2
FEBUXOSTAT TAB 80MG 84BT BE MY	$10.0K	2
FEBUXOSTAT TAB 120MG 28BT IT MY	$8.1K	2
FEBUXOSTAT TAB 80MG 84BL DE MY	$8.0K	1
FEBUXOSTAT TAB 120MG 84BL DE MY	$5.7K	1

Mylan Laboratories Limited exports 10 distinct Febuxostat formulations including tablets, capsules, syrups, and combination drugs. The top formulation is FEBUXOSTAT TAB 120MG 28BL FR MY with 2 shipments worth $100.0K.

How Does Mylan Laboratories Limited Compare to Nearest Febuxostat Exporters?

Exporters ranked immediately above and below #13 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
11	STALLION LABORATORIES PVT LTD	$478.4K	70	2	$6.8K
12	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$449.1K	25	1	$18.0K
13	MYLAN LABORATORIES LIMITED ★	$414.0K	16	5	$25.9K
14	ZYDUS LIFESCIENCES LIMITED	$398.4K	22	5	$18.1K
15	MICRO LABS LIMITED	$392.0K	97	10	$4.0K

Mylan Laboratories Limited ranks #13 among 182 Indian Febuxostat exporters. Average shipment value of $25.9K compared to the market average of $132.8K. The closest competitors by value are STALLION LABORATORIES PVT LTD and SUN PHARMACEUTICAL INDUSTRIES LIMITED.

Which Indian Ports Ship Febuxostat Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	639	18.3%
SAHAR AIR	615	17.6%
DELHI AIR	387	11.1%
SAHAR AIR CARGO ACC (INBOM4)	351	10.0%
NHAVA SHEVA SEA (INNSA1)	145	4.1%
HYDERABAD ICD (INSNF6)	98	2.8%
HYDERABAD AIR	96	2.7%
Bombay Air	84	2.4%

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Febuxostat Exports

Mylan's export operations are influenced by a complex geopolitical landscape. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. Major shipping lines have implemented 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU, directly impacting the cost structure for Indian pharmaceutical exporters like Mylan. Additionally, diversions around the Cape of Good Hope have further elongated delivery schedules, posing challenges to time-sensitive pharmaceutical shipments.

In the United States, the imposition of tariffs on pharmaceutical imports has prompted Indian companies to reassess their market strategies. While generics have largely remained exempt, the potential for future tariff expansions necessitates vigilance. Mylan, along with other Indian exporters, is exploring market diversification to mitigate reliance on the U.S. market. The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, offers a strategic avenue for expansion. The FTA eliminates tariffs on approximately 97% of EU tariff lines, including pharmaceuticals, thereby enhancing market access for Indian exporters. This agreement is expected to significantly boost India's pharmaceutical exports to Europe, providing a counterbalance to uncertainties in the U.S. market.

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Mylan. The FDA's warning letter and import alert in December 2024 concerning the Indore facility underscore the critical importance of stringent quality control measures. The cited violations, including subpar quality control and improper management of manufacturing defects, have necessitated comprehensive corrective actions. Mylan's proactive response aims to restore compliance and reinforce its commitment to quality assurance.

The evolving regulatory environment, particularly in the European Union, further emphasizes the need for adherence to Good Manufacturing Practices (GMP). The EU's Falsified Medicines Directive mandates rigorous compliance to ensure product integrity and patient safety. For Mylan, aligning with these standards is essential to maintain and expand its foothold in the European market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Febuxostat shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Mylan Laboratories Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 16 individual customs records matching Mylan Laboratories Limited exporting Febuxostat, covering 10 formulations to 5 countries via 1 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 91+ countries, 421+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Febuxostat

Febuxostat

Mylan Laboratories Limited — Febuxostat Exporter Profile

Mylan Laboratories Limited — Febuxostat Export Profile: Buyers & Destinations

Where Does Mylan Laboratories Limited Export Febuxostat?

Who Are the Top Buyers of Febuxostat from Mylan Laboratories Limited?

What Is India's Total Febuxostat Export Value and How Much Does Mylan Laboratories Limited Contribute?

What Is the Average Shipment Value for Mylan Laboratories Limited's Febuxostat Exports?

How Does Mylan Laboratories Limited Compare to Other Indian Febuxostat Exporters?

What Febuxostat Formulations Does Mylan Laboratories Limited Export?

How Does Mylan Laboratories Limited Compare to Nearest Febuxostat Exporters?

Which Indian Ports Ship Febuxostat Exports?

Geopolitical & Trade Policy Impact on Mylan Laboratories Limited's Febuxostat Exports

Mylan Laboratories Limited — Regulatory Compliance & Quality Standards

About Mylan Laboratories Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Febuxostat Export Data from Mylan Laboratories Limited

Febuxostat Stats

Company Overview

Top Products by Mylan Laboratories Limited

Related Analysis

Need Detailed Export Data?

Data Source